Bayer Sustainable Development Report 2005 Sustainability Program

Sustainability Program for 2006 onwards


Innovation	Social responsibility
Product stewardship	Responsibility for the environment
Excellence in corporate management

Our Sustainability Program is based around the key areas of innovation, product stewardship, excellence in corporate management, social responsibility and responsibility for the environment. Within each of these areas of action, specific measures are assigned to each objective to ensure that it is achieved by the deadline. The objectives of all the subgroups and service companies have been incorporated into the Group Sustainability Program.

Our objectives by 2010 (unless indicated otherwise)

Objective	Measure
Area of action: Innovation
Promotion of a culture of innovation so that creative ideas and input from all employees can become utilizable for the Group.	Long-term, Group-wide innovation initiative: Implementation of the “Triple-i” program (Inspiration, Ideas and Innovations).
Promotion of research projects on protecting drinking water and freshwater.	Provision of funding and participation in project management for the National Geographic Global Exploration Fund set up by Bayer and National Geographic; in 2006/2007 initiation of socially relevant and innovative projects by external research groups on the new recovery, conservation and fair distribution of water resources.
Contribution to safeguarding the food supply of a growing world population.	Further development of plant biotechnology; development of plants with improved stress tolerance of dry conditions and creation of healthpromoting types of canola.
Tapping potential of renewable resources.	Research work and technological developments for promising applications.
Selective, resource-optimized production ofpharmaceutical active ingredients.	Creation and preparation of therapeutic proteins from plants (plant-made pharmaceuticals).
Provision of improved anticancer drugs.	Extension of indications of the anticancer drug Nexavar® to include liver, skin and lung cancer.
Provision of a drug to combat dangerous circulatory disorders.	Provision of thrombosis prophylaxis in the form of the oral Factor xa inhibitor (BAY 59-7939).
Extension of the duration of efficacy of Kogenate®, a drug recombinant to treat hemophilia.	New formulation based on liposome technology.
Energy conservation by reducing the weight in vehicles using polymer materials, e.g. for windows and structural parts.	Pilot projects with selected car makers and suppliers, for example for roof modules.
Preservation of vital resources by developing innovative polyurethane systems.	Ensuring the availability and high quality of water through the use of innovative and high-quality polyurethane systems for the simple, economical and time-saving rehabilitation of drinking water pipes.
Energy conservation in production processes.	Optimization of a production process for monomeric mdi (MDI = methylene diisocyanate, a raw material used to make polyurethane) for a new large-scale plant in China with a target energy saving of approx. 15 percent.
Area of action: Product stewardship
Ongoing work to secure substance information and its availability for all of our products.	Continuous updating of data records for own production > 1 metric ton, in line with changes to the product portfolio.
Implementation of the objective formulated at Johannesburg on the globally harmonized classification and labeling of substances and preparations.	Support of political interpretation and implementation in conjunction with other relevant regulations (ghs = globally harmonized system).
Improvement in biological effectiveness of crop protection products, coupled with a favorable environmental and health profile.	Management and further development of the Bayer CropScience product portfolio.
Permanent ongoing safeguarding of compliance with regulations on drug safety and quality assurance with regard to human drugs.	Implementation and monitoring of the policy on detailed information obligations, procedures and contact partners for drug safety and quality assurance.
Area of action: Excellence in corporate management
Employment: Ongoing improvement of internal work processes and employee motivation.	Continuation of regular worldwide satisfaction analysis of managerial staff; implementation of global leadership principles coupled with performance assessment, utilization of the experience gained from pilot studies in Italy.
Management of process to implement the Directive on Health, Safety, Environment and Quality (HSEQ) Audits.	Implementation of subgroup-specific HSEQ management systems and complete auditing of these in all regions.
Improvement of communication within the global Bayer organization.	Full implementation of English as Group working language among managers including through the introduction of broadly based training programs.
Improvement of performance of all managers.	Further extension of 360° Feedback processes to include employees with managerial responsibility.
Area of action: Social responsibility
Worldwide promotion of environmental knowledge among young people.	Expansion of cooperation with the United Nations Environment Programme (UNEP), including strengthening of youth environmental networks and capacity building programs in Latin America and Africa.
Strengthening of basic understanding of natural science in schools.	Establishment in Japan of the “Making Science Make Sense” program founded in the United States and already applied in the United Kingdom and Ireland.
Promotion of access to school and vocational education for children and young people, particularly in newly industrializing and developing nations.	Cooperation with regional organizations, initiating own programs to protect and educate young people. Raising of awareness in relevant locations, such as India.
Promotion of education in sustainable development and improvement of environmental awareness in newly industrializing countries (capacity building) in line with voluntary undertaking by the chemical industry based on the Johannesburg Declaration and the ICCM (SAICM).	Development of a training program and financial and HR support for the establishment of a chair in sustainable development at Tongji University in Shanghai, China.
Support for education, science and research.	Reorganization of Bayer foundations focusing more strongly on promoting knowledge and increasing the budget.
Investigation whether the duration of treatment for tuberculosis can be reduced by around half by using the active substance moxifloxacin.	Bayer is collaborating with the Global TB Alliance to supply the active substance moxifloxacin free of charge for a global study program. If the trials are successful, the intention is to have moxifloxacin approved for the indication TB and to make it available to patients in developing countries at affordable prices.
Responsible approach to genetic engineering.	Implementation of new Bayer policy on genetic engineering and specific regulations in the subgroups and service companies.
Occupational safety: Reduction in number of occupational injuries with lost days per 1 million hours worked (MAQ < 2).	Continuation of our consistent safety management approach.
Diversity: Consistent implementation of our corporate values in the area of equal opportunities for all regardless of gender, nationality, color, religion, sexual persuasion or age.	Consistent implementation of Group-wide Program for Legal Compliance and Corporate Responsibility of May 2004; full implementation of a globally harmonized compensation system for Group Leadership Circles 1 to 3.
Area of action: Responsibility for the environment
Water emissions: Ten percent reduction in discharge of tocs and nitrogen into receiving waters per metric ton of sales product. Air emissions: 30 percent reduction in VOC emissions per metric ton of sales product. Air emissions: Further ongoing optimization of energy efficiency in our production plants with the goal of reducing emissions of greenhouse gases by ten percent per metric ton of sales product (by 2015) Air emissions: Compliance with a maximum limit for ods emissions (Ozone Depleting Substances) of less than 20 metric tons per year (CFC 11 equivalents). Waste: Reduction in the volume of hazardous production waste to less than 2.5 percent per metric ton of sales product. Energy consumption: Ten percent reduction in specific energy consumption per metric ton of sold product by 2015.	For competition reasons we do not publicize our measures in this area.